Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- CDFS Recommends 7 Ingredients Including Montelukast, Zolmitriptan for Approval
May 28, 2001
- Protecting, Fostering Innovation Must Be Fundamental Part of Healthcare System: Dr McKinnell of PhRMA
May 28, 2001
- BUSINESS NEWS IN BRIEF -3-
May 28, 2001
- 5 of 7 Firms Including Takeda, Eisai, Daiichi Report Record-high Profits
May 28, 2001
- Classification of Existing Drugs Proposed at Chuikyo
May 28, 2001
- Mitsubishi-Tokyo: Sales Total \84.2 Bil.,Attributable to Growth of Mainstays
May 28, 2001
- Industry Opposes Ministry Data on Prices of Original Products and Generics
May 28, 2001
- Mitsubishi Chemical: Pharmaceutical Sales Top \127.4 Bil.
May 28, 2001
- New Orphan Drugs, Medical Device Announced
May 28, 2001
- WORLD NEWS IN BRIEF
May 28, 2001
- Kyowa Hakko: Drug Sales Down to \141.4 Bil. Due to Suspension of Acenalin Shipment
May 28, 2001
- Industry Must Accept Price Reduction for Long-listed Products: Health Minister
May 28, 2001
- Anti-epileptic Zonisamide to Be Effective against Parkinson's Disease
May 28, 2001
- Teijin: Pharmaceutical Sales Up 1.6% to \88.6 Bil.
May 28, 2001
- None of the Current Proposals Stabilizes Health Insurance Finance: Kenporen Simulation
May 28, 2001
- Seijo: Sales Up 15%, Operating Profits Down 3%
May 28, 2001
- Kobayashi Pharmaceutical: Record-high Sales, Profits
May 28, 2001
- REGULATORY NEWS IN BRIEF
May 28, 2001
- PAJ's Council on Self-medication Promotion to Start Discussions in June
May 28, 2001
- Long-Term Incentives Are Essential to Develop New Drugs: Dr McKinnell
May 28, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…